Clinical Trial: NCT04332367
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
Status:
RECRUITINGPhase:
Phase 2| Lead Sponsor: | Abramson Cancer Center at Penn Medicine |
| Information Provided By: | Abramson Cancer Center at Penn Medicine |
| Last Update Posted: | 2026-06-10 |
Study Overview
Brief Summary
The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.
Official Title
Phase II, Single-Arm Study Of Carboplatin, Weekly Taxane, And Ramucirumab In Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After Progressive Disease On Maintenance Pemetrexed And/Or Pembrolizumab
Conditions
Non-small Cell Lung Cancer
Intervention / Treatment
- Drug: Carboplatin
- Drug: Paclitaxel
- Drug: Ramucirumab
Other Study ID Numbers
- UPCC 05519
- IRB833759
Start Date (Actual)
2020-08-01
Primary Completion Date (Estimated)
2026-09-30
Study Completion Date (Estimated)
2026-09-30
Enrollment (Estimated)
59
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Abramson Cancer Center at Penn Medicine |
| Information Provided By: | Abramson Cancer Center at Penn Medicine |
| Last Update Posted: | 2026-06-10 |
Study Overview
Brief Summary
The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.
Official Title
Phase II, Single-Arm Study Of Carboplatin, Weekly Taxane, And Ramucirumab In Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After Progressive Disease On Maintenance Pemetrexed And/Or Pembrolizumab
Conditions
Non-small Cell Lung Cancer
Intervention / Treatment
- Drug: Carboplatin
- Drug: Paclitaxel
- Drug: Ramucirumab
Other Study ID Numbers
- UPCC 05519
- IRB833759
Start Date (Actual)
2020-08-01
Primary Completion Date (Estimated)
2026-09-30
Study Completion Date (Estimated)
2026-09-30
Enrollment (Estimated)
59
Study Type
Interventional
Phase
Phase 2